secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-006421
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics prices $350M common stock offering at $45.95/share to fund PALSONIFY launch
--------------------------------------------------------------------------------

- Pricing: 7,620,000 shares at $45.95/share; gross proceeds ~$350M.
- Underwriters granted 30-day option to buy up to 1,143,000 additional shares.
- Net proceeds expected ~$330.2M, or ~$379.8M if option exercised.
- Proceeds to fund commercial launch of PALSONIFY, R&D, and general corporate purposes.
- Offering expected to close January 8, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312526006421/0001193125-26-006421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312526006421/d22132d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-006421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer